Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 3
2005 2
2013 2
2014 2
2015 6
2016 1
2018 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Turner NC, et al. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. N Engl J Med. 2015. PMID: 26030518 Free article. Clinical Trial.
Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
Glaspy J, Bondarenko I, Krasnozhon D, Rutty D, Chen J, Fu Y, Wang S, Hou Q, Li S. Glaspy J, et al. Among authors: krasnozhon d. Support Care Cancer. 2024 Jan 9;32(2):91. doi: 10.1007/s00520-023-08260-x. Support Care Cancer. 2024. PMID: 38194162 Free PMC article. Clinical Trial.
Large-Area Epitaxial Monolayer MoS2.
Dumcenco D, Ovchinnikov D, Marinov K, Lazić P, Gibertini M, Marzari N, Lopez Sanchez O, Kung YC, Krasnozhon D, Chen MW, Bertolazzi S, Gillet P, Fontcuberta i Morral A, Radenovic A, Kis A. Dumcenco D, et al. Among authors: krasnozhon d. ACS Nano. 2015 Apr 28;9(4):4611-20. doi: 10.1021/acsnano.5b01281. Epub 2015 Apr 6. ACS Nano. 2015. PMID: 25843548 Free PMC article.
MoS2 transistors operating at gigahertz frequencies.
Krasnozhon D, Lembke D, Nyffeler C, Leblebici Y, Kis A. Krasnozhon D, et al. Nano Lett. 2014 Oct 8;14(10):5905-11. doi: 10.1021/nl5028638. Epub 2014 Sep 22. Nano Lett. 2014. PMID: 25243885
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
Reddy N, Reddy P, Ranpura A, Maharaj N, Arora R, Mamillapalli G, Adhav AS, Diwan AK, Manikhas A, Krasnozhon D. Reddy N, et al. Among authors: krasnozhon d. JCO Glob Oncol. 2024 Jan;10:e2200328. doi: 10.1200/GO.22.00328. JCO Glob Oncol. 2024. PMID: 38237093 Free PMC article. Clinical Trial.
Electrochemical Reaction in Single Layer MoS2: Nanopores Opened Atom by Atom.
Feng J, Liu K, Graf M, Lihter M, Bulushev RD, Dumcenco D, Alexander DT, Krasnozhon D, Vuletic T, Kis A, Radenovic A. Feng J, et al. Among authors: krasnozhon d. Nano Lett. 2015 May 13;15(5):3431-8. doi: 10.1021/acs.nanolett.5b00768. Epub 2015 May 4. Nano Lett. 2015. PMID: 25928894
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Mackey JR, et al. Among authors: krasnozhon d. J Clin Oncol. 2015 Jan 10;33(2):141-8. doi: 10.1200/JCO.2014.57.1513. Epub 2014 Sep 2. J Clin Oncol. 2015. PMID: 25185099 Clinical Trial.
18 results